In the United States, about 1 million people experience heart attacks annually. 375,000 of these, are caused by huge blood clots in the coronary vessels. 200,000 other patients suffer from blood clots in their peripheral arteries. Such clots can be eliminated through a process known as Thrombectomy (blood clot removal).
Thrombolysis, also known as thrombolytic therapy, is a treatment to dissolve these dangerous clots in blood vessels, improve blood flow, and prevent damage to tissues and organs. Catheter-directed thrombolysis treats vascular blockages and improves blood flow by dissolving abnormal blood clots. A blood clot, or thrombus, can block off blood supply to certain parts of the body and cause serious damage. Catheter-directed thrombolysis uses x-ray imaging and a catheter to guide special medication or a medical device to the site of a blood clot to dissolve the blockage.
However, there are shortcomings of the Thrombectomy procedure from the current devices being used in hospitals. The major disadvantage these machines pose is that, they often leave 30% to 50% of the clot as residue. So, it can e require several procedures to get rid of a big clot since they do not completely remove it. They also put patients at high risk because during Thrombectomy there is fragmentation of the blood clot. This is known as Distal Embolization. It’s harmful because it reduces blood flow, causes tissue death and also death.
Thankfully, advances in the removal of blood clots technology has brought about a new innovation called the MegaVac Mechanical Thrombectomy System. It’s composed of four devices. Together, they offer solutions to the limitations of existing systems. The MegaVac completely removes blood clots in arteries, protects against distal embolization, acts as an anchor to other devices and carries out blood clot removal rapidly.
For the millions of people who are at extreme risk of death with blood clots, this new technology is a welcome relief.